Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK-Positive NSCLC Patients: eXalt3.
文献类型：期刊论文
| 作者 | Selvaggi, G.12; Wu, Y.13; Wang, Z.14 ; Wu, G.15; Poddubskaya, E.6; Reck, M.7; Mok, T.8; Chiappori, A.9; Lee, D. H.10; Breder, V.11
|
| 刊名 | JOURNAL OF THORACIC ONCOLOGY
 |
| 出版日期 | 2021-03-01 |
| 卷号 | 16 |
| ISSN号 | 1556-0864 |
| 关键词 | ALK NSCLC ensartinib |
| WOS研究方向 | Oncology ; Respiratory System |
| 语种 | 英语 |
| 出版者 | ELSEVIER SCIENCE INC |
| WOS记录号 | WOS:000631349600306 |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/121756]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 作者单位 | 1.Stanford Univ, Dept Med, Div Oncol, Stanford Canc Inst, Stanford, CA 94305 USA 2.Vanderbilt Ingram Canc Ctr, Hematol Oncol, Nashville, TN USA 3.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China 4.China Med Univ, Affiliated Hosp 1, Shenyang, Peoples R China 5.Jilin Canc Hosp, Jilin, Jilin, Peoples R China 6.Sechenov Univ, Clin Ctr Oncol, Moscow, Russia 7.Airway Res Ctr North Arcn, Lung Clin, Grosshansdorf, Germany 8.Chinese Univ Hong Kong, Clin Oncol, Hong Kong, Peoples R China 9.H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA 10.Asan Med Ctr, Seoul, South Korea |
| 推荐引用方式 GB/T 7714 | Selvaggi, G.,Wu, Y.,Wang, Z.,et al. Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK-Positive NSCLC Patients: eXalt3.[J]. JOURNAL OF THORACIC ONCOLOGY,2021,16. |
| APA | Selvaggi, G..,Wu, Y..,Wang, Z..,Wu, G..,Poddubskaya, E..,...&Wakelee, H. A..(2021).Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK-Positive NSCLC Patients: eXalt3..JOURNAL OF THORACIC ONCOLOGY,16. |
| MLA | Selvaggi, G.,et al."Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK-Positive NSCLC Patients: eXalt3.".JOURNAL OF THORACIC ONCOLOGY 16(2021). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。